Skip to content

Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers

Nasopharyngeal 24 Hour pH Monitoring in Health Adult Volunteers

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00584675
Enrollment
0
Registered
2008-01-02
Start date
2007-02-28
Completion date
2008-02-29
Last updated
2015-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Reflux Disease

Keywords

GERD, laryngopharyngeal reflux disease

Brief summary

Involves a 24-hour pH probe study using the Dx-pH Measurement System on patients who do not have symptoms of laryngopharyngeal reflux or gastroesophageal reflux disease to establish normal values for the Dx-pH Measurement System.

Detailed description

The specific aim of this study is to establish the normal range of values in an adult population with no symptoms of laryngopharyngeal reflux disease or gastroesophageal reflux disease using the Dx-pH Measurement System.

Interventions

DEVICEDx-pH Measurement Probe

Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.

Sponsors

University of California, Davis
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years of age or older * no symptoms of laryngopharyngeal reflux or gastroesophageal reflux disease * score less than 10 on Reflux Symptom Index

Exclusion criteria

* age less than 18 * known lidocaine allergy * history of heartburn, regurgitation, chronic cough, voice changes, globus pharyngeus, excessive throat clearing, or swallowing problems * score 10 or greater on Reflux Symptom Index * current or past antacid use or other antireflux therapy * history of antireflux surgery * pregnancy * current anticoagulation therapy (warfarin, heparin, aspirin, clopidogrel bisulfate) * special/vulnerable populations (children, mentally handicapped, pregnant women, fetuses, prisoners, cognitive impairment, life-threatening disease, social or economic disadvantage)

Design outcomes

Primary

MeasureTime frame
To develop a range of normal values in adults without symptoms of laryngopharyngeal reflux.At completion of study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026